Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.
Alexander M M Eggermont, Stefan Suciu, Piotr Rutkowski, Willem H Kruitand 6 more
